These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31925675)

  • 1. Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    States V; O'Brien S; Rai JP; Roberts HL; Paas M; Feagins K; Pierce EJ; Baumgartner RN; Galandiuk S
    Dig Dis Sci; 2020 Sep; 65(9):2675-2685. PubMed ID: 31925675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease.
    Menachem Y; Gotsman I
    Isr Med Assoc J; 2004 Feb; 6(2):88-90. PubMed ID: 14986464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
    J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.
    King D; Chandan JS; Thomas T; Nirantharakumar K; Reulen RC; Adderley NJ; Trudgill N
    Inflamm Bowel Dis; 2021 Oct; 27(11):1731-1739. PubMed ID: 34669933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.
    Farhi D; Cosnes J; Zizi N; Chosidow O; Seksik P; Beaugerie L; Aractingi S; Khosrotehrani K
    Medicine (Baltimore); 2008 Sep; 87(5):281-293. PubMed ID: 18794711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular Manifestations in Inflammatory Bowel Disease Are Associated with Other Extra-intestinal Manifestations, Gender, and Genes Implicated in Other Immune-related Traits.
    Taleban S; Li D; Targan SR; Ippoliti A; Brant SR; Cho JH; Duerr RH; Rioux JD; Silverberg MS; Vasiliauskas EA; Rotter JI; Haritunians T; Shih DQ; Dubinsky M; Melmed GY; McGovern DP
    J Crohns Colitis; 2016 Jan; 10(1):43-9. PubMed ID: 26449790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucocutaneous manifestations in inflammatory bowel disease.
    Yüksel I; Başar O; Ataseven H; Ertuğrul I; Arhan M; Ibiş M; Dağli U; Demirel BT; Ulker A; Seçilmiş S; Saşmaz N
    Inflamm Bowel Dis; 2009 Apr; 15(4):546-50. PubMed ID: 19023896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
    Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
    Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Kilic Y; Kamal S; Jaffar F; Sriranganathan D; Quraishi MN; Segal JP
    Inflamm Bowel Dis; 2024 Feb; 30(2):230-239. PubMed ID: 37042969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extraintestinal manifestations in inflammatory bowel disease: Prevalence and predictors in Indian patients.
    Bandyopadhyay D; Bandyopadhyay S; Ghosh P; De A; Bhattacharya A; Dhali GK; Das K
    Indian J Gastroenterol; 2015 Sep; 34(5):387-94. PubMed ID: 26614005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral arthritis in the course of inflammatory bowel diseases.
    Yüksel I; Ataseven H; Başar O; Köklü S; Ertuğrul I; Ulker A; Dağlı U; Saşmaz N
    Dig Dis Sci; 2011 Jan; 56(1):183-7. PubMed ID: 20458624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services' Adult Hospital 1998-2009.
    Polcz M; Gu J; Florin T
    J Crohns Colitis; 2011 Apr; 5(2):148-51. PubMed ID: 21453884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.
    Karmiris K; Avgerinos A; Tavernaraki A; Zeglinas C; Karatzas P; Koukouratos T; Oikonomou KA; Kostas A; Zampeli E; Papadopoulos V; Theodoropoulou A; Viazis N; Polymeros D; Michopoulos S; Bamias G; Kapsoritakis A; Karamanolis DG; Mantzaris GJ; Tzathas C; Koutroubakis IE
    J Crohns Colitis; 2016 Apr; 10(4):429-36. PubMed ID: 26721936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking increases the risk of extraintestinal manifestations in Crohn's disease.
    Ott C; Takses A; Obermeier F; Schnoy E; Müller M
    World J Gastroenterol; 2014 Sep; 20(34):12269-76. PubMed ID: 25232261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
    Roth N; Biedermann L; Fournier N; Butter M; Vavricka SR; Navarini AA; Rogler G; Scharl M;
    PLoS One; 2019; 14(1):e0210436. PubMed ID: 30682031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extraintestinal manifestations of inflammatory bowel disease and intestinal tuberculosis: Frequency and relation with disease phenotype.
    Singh B; Kedia S; Konijeti G; Mouli VP; Dhingra R; Kurrey L; Srivastava S; Pradhan R; Makharia G; Ahuja V
    Indian J Gastroenterol; 2015 Jan; 34(1):43-50. PubMed ID: 25663290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
    Juliao-Baños F; Arrubla M; Osorio L; Camargo J; Londoño J; Cáceres C; Carvajal J; Mosquera-Klinger G; Donado J
    Gastroenterol Hepatol; 2021; 44(6):398-404. PubMed ID: 33172691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.
    He R; Zhao S; Cui M; Chen Y; Ma J; Li J; Wang X
    Front Immunol; 2023; 14():1234535. PubMed ID: 37954590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Zheng DY; Wang YN; Huang YH; Jiang M; Ma YN; Dai C
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1745-1759. PubMed ID: 38740543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.